SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (2606)1/18/2001 3:05:55 PM
From: Jibacoa  Respond to of 52153
 
BGEN:

As you said, fundamentals look good.

However, there is (from the "technical" standpoint) some overhead resistance, due to the "triple-top" from the Hs on Sept.28, Nov.3 and Dec.21& 28 at the 64 1/2 to 65 level.

Once it is able to deal with that hurdle, then there is still some resistance at the early Jul.H at 75 5/8 and before that some of the Aug. H at 72 1/2.

After it is able to close at 76, there is a much likely probability (I don't know what the p-value on that is) that it will keep the upwards momentum at an accelerated pace.

As you recall BGEN's H last year in February was 129.

Bernard



To: Mark Bong who wrote (2606)2/1/2001 12:51:07 PM
From: aknahow  Read Replies (1) | Respond to of 52153
 
<<<the blockbuster potential of Amevive is not reflected in the stock price>>>>

In a recent statement BGEN said the P III dosing had been completed, yet user threads show subjects still receiving treatment with about 10 more weeks to go> What am I missing?

How do you feel the results announced thus far compare to those released by competitors?

Thanks.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News